Evaluating prostate needle biopsy: Therapeutic and prognostic importance

Ca-A Cancer Journal for Clinicians

Volumn 47, Issue 5, 1997, Pages 297-319

  Bostwick, David G ^a  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ANDROGEN; COLLAGEN; KERATIN; MUCIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER GRADING; CANCER INVASION; CANCER RADIOTHERAPY; CRYOSURGERY; CRYSTALLOID; CYTOLOGY; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NEEDLE BIOPSY; PLOIDY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE CARCINOMA; PROSTATECTOMY;

EID: 0030870320     PISSN: 00079235     EISSN: None     Source Type: Journal    
DOI: 10.3322/canjclin.47.5.297     Document Type: Article

References (135)

1. Bostwick DG, Vonk J, Picado A: Pathologic changes in the prostate following contemporary 18-gauge needle biopsy: No apparent risk of local cancer seeding. J Urol Pathol 1994;2:203-212.
2. Terris MK, McNeal JE, Stamey TA: Detection of clinically significant prostate cancer by transrectal ultrasound-guided systematic biopsies. J Urol 1992;148:829-832.
3. Hammerer P, Huland H, Sparenberg A: Digital rectal examination, imaging, and systematic-sextant biopsy in identifying operable lymph node-negative prostatic carcinoma. Eur Urol 1999;22:281-287.
4. Stamey TA, Freiha FS, McNeal JE, et al: Localized prostate cancer: Relationship of tunor volume to clinical significance for treatment of prostate cancer. Cancer 1993;71(Suppl 3):933-938.
5. Eskew LA, Bare RL, McCullough DL. Systematic 5 region prostrate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol 1997;157:199-203
6. Ryan PG, Peeling WB: Perineal prostatic tumour seeding after Tru-Cut needle biopsy: Case report and review of the literature. Eur Urol 1990;17:189-192.
7. Moul JW, Miles BJ, Skoog SJ, et al: Risk factors for perineal seeding of prostate cancer after needle biopsy. J Urol 1989;142:86-88.
8. Bastacky SS, Walsh PC, Epstein JI: Needle biopsy associated tumor tracking of adenocarcinoma of the prostate. J Urol 1991;145:1003-1007.
9. Blight EM Jr: Seeding of prostate adenocarcinoma following transrectal needle biopsy. Urology 1992;39:297-298.
10. Coley CM, Barry MJ, Fleming C, et al: Early detection of prostate cancer. Part I: Prior probability and effectiveness of tests; the American College of Physicians. Ann Intern Med 1997;126:394-406.
11. Shaw EB, Wofford ED, Carter J: Processing prostate needle biopsy specimens for 100% detection of carcinoma. Am J Clin Pathol 1995;103:507 Abstract.
12. Daneshgari F, Taylor GD, Miller GJ, et al: Computer simulation of the probability of detecting low volume carcinoma of the prostate with six random systematic core biopsies. Urology 1995;45:604-609.
13. Uzzo RG, Wei JT, Waldbaum RS, et al: The influence of prostate size on cancer detection. Urology 1995;46:831-836.
14. Karakiewiez PI, Bazinet M, Aprikian AG, et al: Outcome of sexant biopys accourding to gland volume. Urology 1997;49:55-59.
15. Keetch DW, Catalona WJ, Smith DS: Serial prostatic biopsies in men with persisently elevated serum prostatic specific antigen values. J Urol 1994;151:1571-1574.
16. Ellis WJ, Brawer MK: Repete prostate needle biopsy: Who needs it? J Urol 1995;153:1496-1498.
17. Roehrborn CG.Pickens GJ, Sanders JS: Diagnostics yield of repeated transrectal ultrasound-guide biopsies stratified by specific histopathologic diagonoses and prostate-specifics antigens levels. Urology 1996;47:347-352.
18. Stroumbakis N, Cookson MS, Reuter VE,et al: Clinical significance of repeat sextant biopsies in prostate cancer patients. Urology 1997;49 (Suppl 3A):113-118.
19. AlgabaF, Epstein JI, Aldape HC, et al: Assessment of prostate carcinoma in core needle biopsy: Definition of minimal criteria for the diagnosis of cancer in biopsy material. Cancer 1996;78:376-381.
20. Shepherd D, Keetch DW, Humphrey PA, et al: Repeat biopsy strategy in men with isolated prostattic intraepithelial neoplasia on prostate needle biopsy. J Urol 1996;156:460-463.
21. Morgan TO, MeLeod DG, Leifer ES, et al: Prospective use of free prostate-specfic antigen to avoid repat prostate biopsies in men with elevated total prostate-specfic antigen. Urology 1996;48(Suppl 6A):76-80.
22. Renshaw AA: Adequate tissue sampling of prostate core needle biopises. Am J Clin Pathol 1997;107:26-29.
23. Brostwick DG, Dundore PA; Biopsy Interpretation of the Prostat. London, Chapman & Hall, 1997.
24. Goldstein NS, Qian J, Bostwick DG. Mucin expression in atypical adenomatous hyperplasia of the prostate. Hum Pathol 1995;26:887-891.
25. Del Rosario AD, Bui HX, Abdulla M, et al: Sulfur-rich prostatic intraluminal crystalloids: A surgical pathologic and electron probe x-ray microanalytic study. Hum Pathol 1993;24:1159-1167.
26. Molberg KH, Mikhail A, Vuitch F: Crystalloids in metastatic prostatic adenocarcinoma Am J Clin Pathol 1994;101:266-268.
27. Bostwick DG, Wollan P, Adlakha K: Collagenous micromodules in prostate cancer: A specific but infrequent diagnostic finding. Arch Pathol Lab Med 1995;119:444-447.
28. Darson MF, Pacelli A, Roche P, et al: Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: A novel prostate cancer marker. Urology 1997;49:857-862.
29. Bostwick DG: Prostate-specific antigen:Current role in diagnostic pathology of prostate cancer. Am J Clin Pathol 1994;102(Suppl 1):531-537.
30. Brawn PN, Foster DM, Jay DW, et al: Characteristics of prostatic infarcts and their effect on serum prostate-specific antigen and prostatic acid phosphatase. Urology 1994;44:71-75.
31. Lowe FC, Trauzzi SJ: Prostatic acid phosphatase in 1993: Its limited clinical utility. Urol Clin North Am 1993;20:589-595.
32. Bostwick DG, Brawer MK: Prostatic intraepithelial neoplasia and early invasion in prostate cancer. Cancer 1987;59:788-794.
33. Brawer MK, Peehl DM, Stamey TA, et al: Keratin immunoreactivity in the benign and neoplastic human prostate. Cancer Res 1985;45:3663-3667.
34. Cheville JC, Bostwick DG: Postatrophic hyperplasia of the prostate; A histologic mimic of prostate adenocarcinoma. Am J Surg Pathol 1995;19:1068-1076.
35. Kostwick DG: High-grade prostatic intraepithelial neoplasia: The most likely precursor of prostate cancer. Cancer 1995;75:1823-1836.
36. Sakr WA, Grignon DJ. Haas GP, et al: Epidemiology of high-grade prostatic intraepithelial neoplasia. Pathol Res Pract 1995;191:838-841.
37. Billis A: Age and race distribution of high-grade prostatic intraepithelial neoplasia. An autopsy study in Brazil (South America) J Urol Pathol 1996;5:1-7
38. Mettlin C, Lee F, Drago J, et al: The American Cancer Society National Prostate Cancer Detection Project: Findings of the detection of early prostate cancer in 2425 men. Cancer 1991;67:2949-2958.
39. Bostwick DG, Qian J, Frankel K: The incidence of high-grade prostatic intraepithelial neoplasia in needle biopsies. J Urol 1995;154:1791-1794.
40. Bostwick DG, Pacelli A, Lopez-Beltran A: Molecular biology of prostatic intraepithelial neoplasia Prostate 1996;29:117-134.
41. Davidson D, Bostwick DG, Qian J, et al: Prostatic intraepithelial neoplasia is a risk factor for adenocarcinoma: Predictive accuracy in needle biopsies. J Urol 1996;154:1295-1299.
42. Berner A, Danielsen HE, Pettersen EO, et al: DNA distribution in the prostate: Normal gland. benign and premalignant lesions, and subsequent adenocarcinomas. Anal Quant Cytol Histol 1993;15:247-252.
43. Weinstein MH, Epstein JI Significance of high-grade prostatic intraepithelial neoplasia on needle biopsy. Hum Pathol 1993;24:624-629.
44. Aboseif S, Shinohara K, Weidner N, et al: The significance of prostatic intra-epithelial neoplasia. Br J Urol 1995;76:355-359.
45. Keetch DW, Humphrey P, Stahl D, et al: Morphometric analysis and clinical followup of isolated prostatic intraepithelial neoplasia in needle biopsy of the prostate. J Urol 1995;154:347-351.
46. Raviv G, Zlotta AR, Janssen TH, et al: Do prostate specific anitgen and prostate specific antigen density enhance the detection of prostate, carcinoma after initial diagnosis of prostatic intraepithelial neoplasia without concurrent carcinoma? Cancer 1996;77:2103-2108.
47. Langer JE, Rovner ES, Coleman BG, et al: Strategy for repeat biopsy of patients with prostatic intraepithelial neopiasia detected by prostate needle biopsy. J Urol 1996;155;228-231.
48. Cheville JC, Reznicek MJ, Clark JR, et al: The focus of atypical glands suspicious for malignancy in prostate needle biopsy specimens: Incidence, histologic features, and clinical follow-up of cases diagnosed in a community practice. Am J Clin Pathol 1997, in press.
49. Iczkowski K, MacLennan GT, Bostwick DG: Atypical small acinar proliferation of the prostate suspicious for malignancy in needle biopsies: Histologic features and clinical significance in 33 cases. Am J Surg Pathol 1997, in press.
50. Henson DE, Hutter RV, Farrow G: Practice protocol for the examination of specimens removed from patients with carcinoma of the prostate gland: A publication of the Cancer Committee, College of American Pathologists Task Force on the Examination of Specimens Removed from Patients with Prostate Cancer. Arch Pathol Lab Med 1994;118:779-783.
51. Amin MB, Grignon D, Bosiwick D, et al: Recommendations for the reporting of resected prostate carcinomas: Association of Directors of Anatomic and Surgical Pathology. Am J Clin Pathol 1996;105:667-670.
52. Dugan TC, Shipley WU, Young RH, et al: Biopsy after external beam radiation therapy for adenocarcinoma of the prostate: Correlation with original histological grade and current prostate specific antigens levels, J Urol 1991;146:1313-1316.
53. Kabalin JN: Biopsy after external beam radiation therapy for adenocarcinoma of the prostate: Correlation with original histological grade and current prostate specific antigen levels. J Urol 1992;148:1565-1566, Letter.
54. Siders DB, Lee F: Histologic changes of irradiated prostatic carcinoma diagnosed by transrectal ultrasound. Hum Pathol 1992;23:344-351.
55. Wheeler JA, Zagars GK, Ayala AG: Dedifferentiation of locally recurrent prostate cancer after radiation therapy. Evidence for tumor progression Cancer 1993;71:3783-3787.
56. Prestidge BR. Hoak DC, Grimm, PD, et al; Posttreatment biopsy results following interstitial brachytherapy in early-stage prostate cancer Int J Radiat Oncol Biol Phys 1997;37:31-39.
57. Crook JM, Bahadur YA, Bociek RG, et al: Radiotherapy for localized prostate carcinoma: The correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with out-come as as assessed by systematic biopsy and serum prostate specific antigen. Cancer 1997;79:328-336.
58. Tetu B, Srigley JR, Boivin JC, et al: Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma: Ahistopathologic and immunohistochemical study. Am J Surg Pathol 1991;15:111-120.
59. Ferguson J, Zincke H, Ellison E, et al: Decrease of prostatic intraepithelial neoplasia following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy. Urology 1994;44:91-95.
60. Böcking A, Auffermann W: Cytological grading of therapy-induced tumor regression in prostatic carcinoma: Proposal of a new system. Diagn Cytopathol 1987;3:108-111.
61. Murphy WM, Soloway MS, Barrows GH, Pathologic changes associated with androgen deprivation therapy for prostate cancer. Cancer 1991;68:821-828.
62. Hellström M, Häggman M, Brändstedt S, et al: Histopathological changes in androgen-deprived localized prostatic cancer: A study in total prostatectomy specimens. Eur Urol 1993;24:461-465.
63. Armas OA, Aprikian AG, Melamed J, et al: Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma. Am J Surg Pathol 1994;18:979-991.
64. Montironi R, Magi-Galluzzi C, Muzzonigro G, et al: Effects of combination endocrine treatment on normal prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma. J Clin Pathol 1994;47:906-913.
65. Smith DM, Murphy WM: Histologic changes in prostate carcinomas treated with leuprolide (luteinizing hormone-releasing hormone effect): Distinction from poor tumor differentiation. Cancer 1994;73:1472-1477.
66. Civantos F, Marcial MA, Banks ER, et al: Pathology of androgen depriviation therapy in prostatic carcinoma. A comparative study of 173 patients. Cancer 1995;75:1634-1641.
67. Ellison E, Chuang SS, Zincke H, et al: Prostate adenocarcinoma after androgen deprivation therapy: A comparative study of morphology, morphometry, immunohistochemistry and DNA ploidy. Pathol Case Reviews 1996;1:37-47.
68. Shabaik A, Wilson S. Bidair M, et al: Pathologic changes in prostate biopsies following cryoablation therapy of prostate carcinoma. J Urol Pathol 1995;3:183-194.
69. Borkowski P, Robinson MJ, Poppiti RJ Jr, et al: Histologic findings in postcryosurgical prostatic biopsies. Mod Pathol 1996;9:807-811.
70. Falconieri G, Lugnani F, Zanconati F. et al: Histopathology of the frozen prostate: The microscopic bases of prostatic carcinoma cryoablation. Pathol Res Pract 1996;192:579-587.
71. Shuman BA, Cohen JK, Miller RJ Jr, et al: Histological presence of viable prostatic glands on routine biopsy following cryosurgical ablation of the prostate. J Urol 1997;157:552-555.
72. Isaacs JT: Molecular markers for prostate cancer metastases: Developing diagnostic methods for predicting asgressiveness of prostate cancer. Am J Pathol 1997;150:1511-1521.
73. Grignon DJ, Hammond EH: College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors: Report of the Prostate Cancer Working Group. Arch Pathol Lab Med 1995;119:1122-1126.
74. Terris MK, Pham TQ, Issa MM, et al: Routine transition zone and seminal vesicle biopsies in all patients undergoing transrectal ultrasound guided prostate biopsies are not indicated. J Urol 1947;157:204-206.
75. Keetch DW, Catalona WJ: Prostatic transition zone biopsies in men with previous negative biopsies and persistently elevated serum prostate specific antigen values. J Urol 1995;154:1795-1797.
76. Bazinet M, Karakiewicz PI, Aprikian AG, et al: Value of systematic transition zone biopsies in the early detection of prostate cancer. J Urol 1996;155:605-606.
77. Pandey P, Fowler JE Jr, Seaver LE, et al: Ultrasound guided seminal vesicle biopsies in men with suspected prostate cancer. J Urol 1995;154:1798-1803.
78. Stone NN, Stock RG, Unger P: Indications for seminal vesicle biopsy and laparoscopic pelvic lymph node dissection in men with localized carcinoma of the prostate. J Urol 1995; 154:1392-1396.
79. Linzer DG, Stock RG, Stone NN, et al: Seminal vesicle biopsy Accuracy and implications for stagins of prostate cancer. Urology 1996;48:757-761.
80. Allepuz Losa CA, Sanz Velez JI, Gil Sanz MJ, et al: Seminal vesicle biopsy in prostate cancer staging. J Urol 1995;154:1407-1411.
81. Epstein JI, Walsh PC, Carmichael M. et al: Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:368-374.
82. Haggman M, Nybacka O, Nordin B, et al: Standardized in vitro mapping with multiple core biopsies of total prostatectomy specimens: Localization and prediction of tumour volume and grade. Br J Urol 1994;74:617-625.
83. Irwin MB, Trapasso JG: Identification of insignificant prostate cancers: Analysis of preoperative parameters. Urology 1994;44:868-868.
84. Cupp MR, Bostwick DG, Myers RP, et al: The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis. J Urol 1995;153:1543-1548.
85. Humphrey PA, Baty J, Keetch D: Relationship between serum prostate specific antigen, needle biopsy findings, and histopathologic features of prostatic carcinoma in radical prostatectomy tissues. Cancer 1995;75:1842-1849.
86. Weldon VE, Tavel FR, Neuwirth H, et al: Failure of focal prostate cancer on biopsy to predict focal prostate cancer: The importance of prevalence, J Urol 1995;154:1074-1077.
87. Bruce RG, Rankin WR, Cibull ML, et al: Single focus of adenocarcinoma in the prostate biopsy specimen is not predictive of pathologic stage of disease. Urology 1996;48:75-79.
88. Goto Y, Ohori M, Arakawa A, et al: Distinguishing clinically important from unimportant prostate cancers before treatment: Value of systematic biopsies. J Urol 1996;156:1059-1063.
89. Ravery V, Schmid HP, Toubianc M, et al: Is the percentage of cancer in biopsy cores predictive of extracapsular disease in T1-T2 prostate carcinoma? Cancer 1996;78:1079-1084.
90. Lee WR, Hanlon AL, Hanlon AL, Hanks GE: Systematic biopsies: Do they add prognostic information in men with clinically localized prostate cancer treated with radiation therapy alone? Radiology 1996;198:439-442.
91. Bibbo M, Bartels PH, Pfeifer T, et al: Belief network for grading prostate lesions. Anal Quant Cytol Histol 1993;15:124-135.
92. Bostwick DG: Gleason grading of prostatic needle biopsies: Correlation with grade in 316 matched prostatectomies. Am J Surg Pathol 1994;18:796-803.
93. Spires SE, Cibull ML, Wood DP Jr, et al: Gleason histologic grading in prostatic carcinoma: Correlation of 18-gauge core biopsy with prostatectomy. Arch Pathol Lab Med 1994;118:705-708.
94. Kojima M, Troncoso P, Babaian RJ: Use of prostate-specific antigen and tumor volume in predicting needle biopsy grading error. Urology 1995;45:807-812.
95. Thickman D, Speers WC, Philpott PJ, et al: Effect of the number of core biopsies of the prostate on predicting Gleason score of prostate cancer. J Urol 1996;156:110-113.
96. Cookson MS, Ffeshner NE, Soloway SM, et al: Correlation between Gleason score of Needle biopsy and radical prostatectomy specimen: Accuracy and clinical implications J Urol 1997;157:559-562.
97. Steinberg DM, Sauvageot J, Piantadosi S, et al: Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings Am J Surg Pathol 1997;21:566-576.
98. Gleason DF: Histologic grading of prostate cancer: A perspective Hum Pathol 1992;23:273-279.
99. Aihara M, Wheeler TM, Ohori M, et al: Heterogeneity of prostate cancer in radical prostatectomy specimens. Urology 1994;43:60-66.
100. Egan AJM, Bostwick DG: Prediction of extraprostatic extension of prostate cancer based on needle biopsy findings Perineural invasion lacks significance on multivariate analysis. Am J Surg Pathol 1997, in press.
101. Bonin SR, Hanlon AL, Lee WR, et al: Evidence of increased failure in the treatment of prostate carcinoma patients who have perineural invasion treated with three-dimentional conformal radiation therapy. Cancer 1997;79:75-80.
102. Salomao DR, Graham SD, Bostwick DG: Microvascular invasion in prostate cancer correlates with pathologic stage. Arch Pathol Lab Med 1995;119:1050-1054.
103. Bahnson RR, Dresner SM, Gooding W, et al: Incidence and prognostic significance of lymphatic and vascular invasion in radical prostatectomy specimens. Prostate 1989;15:149-155.
104. Montironi R, Galluzzi CM, Diamanti L, et al: Prostatic intra-epithelial neoplasia. Qualitative and quantitative analyses of the blood capillary architecture on thin tissue sections. Pathol Res Pract 1993;189:542-548.
105. Wakui S, Furusato M, Itoh T, et al: Tumour angiogenesis in prostatic carcinoma with and without bone marrow metastasis: A morphometric study. J Pathol 1992;168:257-262.
106. Weidner N, Carroll PR, Flax J, et al: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993;143:401-409.
107. Brawer MK, Deering RE, Brown M, et al: Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity. Cancer 1994;73:678-687.
108. Siegal JA, Yu E, Brawer MK: Topography of neovascularity in human prostate carcinoma. Cancer 1995;75:2545-2551.
109. Bostwick DG, Wheeler TM, Blute M, et al: Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. Urology 1996;48:47-57.
110. Hall MC, Troncoso P, Pollack A, et al: Significance of tumor angiogenesis in clinically localized prostate carcinoma treated with external beam radiotherapy. Urology 1994;44:869-875.
111. Vesalainen S, Lipponen P, Talja M, et al: Tumor vascularity and basement membrane structure as prognostic factors in T1-2MO prostatic adenocarcinoma. Anticancer Res 1994;14:709-714.
112. Silberman MA, Partin AW, Veltri RW, et al: Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate. Cancer 1997;79:772-779.
113. Jones EC, McNeal J, Bruchovsky N, et al: DNA content in prostatic adenocarcinoma: A flow cytometry study of the predictive value of aneuploidy for tumor volume, percentage Gleason grade 4 and 5, and lymph node metastases. Cancer 1990;66:752-757.
114. Warzynski MJ, Soechtig CE, Maatman TJ, et al: DNA analysis by flow cytometry of paraffin embedded core biopsies of the prostate. Prostate 1994;24:313-319.
115. Tribukait B: Nuclear deoxyribonucleic acid determination in patients with prostate carcinomas: Clinical research and application. Eur Urol 1993;23(Suppl 2):64-76.
116. Zincke H, Bergstrahl EJ, Larson-Keller JJ, et al: Stage D1 prostate cancer treated by radical prostate- ctomy and adjuvant hormonal treatment. Evidence for favorable survival in patients with DNA diploid tumors. Cancer 1992;70(Suppl 1):311-323.
117. Forsslund G. Esposti PL, Nilsson B, et al: The prognostic significance of nuclear DNA content in prostatic carcinoma. Cancer 1992;69;1432-1439.
118. van den Ouden D, Tribukait B, Blom JH, et al: Deoxyribonucleic acid ploidy of core biopsies and metastatic lymph nodes of prostate cancer patients: Impact on time to progression. J Urol 1993;150:400-406.
119. Greene DR, Rogers E, Wessels EC, et al: Some small prostate cancers are nondiploid by nuclear image analysis: Correlation of deoxyribonucleic acid ploidy status and pathological features J Urol 1994;151:1301-1307.
120. Baretton GB, Vogt T, Blasenbreu S, et al: Comparison of DNA ploidy in prostatic intraepithelial neoplasia and invasive carcinoma of the prostate: An image cytometric study. Hum Pathol 1994;25:506-513.
121. Takai K, Goellner JR, Katzmann JA, et al: Static image and flow DNA cytometry of prostatic adenocarcinoma: Studies of needle biopsy and radical prostatectomy specimens. J Urol Pathol 1994;2:39-48.
122. Lo J, Kerns BJ, Amling CL, et al: Correlation of DNA ploidy and histologic diagnosis from prostate cort-needle biopsies: Is DNA ploidy more sensitive than histology for the diagnosis of carcinoma in small specimens? J Surg Oncol 1996;63:41-45
123. Shankey TV, Kallioniemi OP, Koslowski JM, et al: Consensus review of the clinical utility of DNA content cytometry in prostate cancer, Cytometry 1993;14:497-500.
124. Bluestein DL, Bostwick DG, Bergstralh EJ, et al: Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer. J Urol 1994;151:1315-1320.
125. Roach M 3rd, Marquez C, Yuo HS, et al: Predicting the risk of lymph node involvement using the pre-treatment prostate-specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1994;28:33-37.
126. Narayan P, Gajendran V, Taylor SP, et al: The role of transrectal ultrasound-guided biopsy-based staging, preoperative serum prostate-specific antigen, and biopsy Gleason score in prediction of final pathologic diagnosis in prostate cancer. Urology 1995;46:205-212.
127. Boccon-Gibod L: Significant versus insignificant prostate cancer: Can we identify the tigers from the pussy cats? J Urol 1996;156:1069-1070. Editorial.
128. Bostwick DG. Qian J, Bergstralh E, et al Prediction of capsular perforation and seminal vesicle invasion in prostate cancer. J Urol 1996;155:1361-1367.
129. Pisansky TM, Blute ML, Suman VJ, et al: Correlation of pretherapy prostate cancer charcteristics with seminal vesicle invasion in radical prostatectomy specimens. Int J Radiat Oncol Biol Phys 1996;36:585-591.
130. Rogers E, Gurpinar T, Dillioglugil O, et al: The role of digital rectal examination, biopsy Gleason sum and prostate-specific antigen in selecting patients who require pelvic lymph node disseetions for prostate cancer. Br J Urol 1996;78:419-425.
131. D'Amico AV, Whittington R, Malkowicz SB, et al: Combined modality staging of prostate carcinoma and its utility in predicting pathologic stage and postoperative prostate specific antifen failure. Urology 1997;49(Suppl 3A):23-30.
132. Kattan MW, Stapleton AM, Wheeler TM, et al: Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate car cinoma, Cancer 1997;79:528-537.
133. Partin AW, Kattan MW, Subong EN, et al: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update. JAMA 1997;277:1445-1451.
134. Pisansky TM, Kahn MJ, Rasp GM, et al: A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostatic carcinoma. Cancer 1997;79:337-344.
135. Burke HB, Goodman PH, Rosen DB, el al: Artificial neural networks improve the accuracy of cancer survival prediction. Cancer 1996;79:857-862.